Internal Medicine, Pulmonology, The Medical School and Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.
Research, Humeltis Ltd, Pecs, Baranya, Hungary.
BMJ Open Respir Res. 2020 Jun;7(1). doi: 10.1136/bmjresp-2019-000505.
Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response.Methods Tumour cells were isolated from resected solid tumours or pleural effusions, and cryopreserved. Three-dimensional (3D) tissue aggregate cultures were set up when the oncoteam reached therapy decision for individual patients. The aggregates were then treated with the selected drug or drug combination and in vitro chemosensitivity was tested individually measuring ATP levels. The clinical response to therapy was assessed by standard clinical evaluation over an 18 months period.Results Based on the data, the in vitro chemosensitivity test results correlate well with clinical treatment response.Conclusions Such tests if implemented into the clinical decision making process might allow the selection of an even more individualised chemotherapy protocol which could lead to better therapy response.
尽管筛查技术有所提高，但肺癌的诊断往往较晚，预后较差。在本研究中，分析并比较了肺腺癌实体瘤和胸腔积液的体外化疗敏感性与临床药物反应。
从切除的实体瘤或胸腔积液中分离肿瘤细胞，并进行冷冻保存。当肿瘤团队为个别患者做出治疗决策时，建立三维（3D）组织聚集培养物。然后用选定的药物或药物组合处理聚集物，并单独测量 ATP 水平来测试体外化疗敏感性。通过标准临床评估在 18 个月的时间内评估治疗的临床反应。
基于这些数据，体外化疗敏感性测试结果与临床治疗反应密切相关。
如果将此类测试纳入临床决策过程中，可能会选择更个体化的化疗方案，从而提高治疗反应。
